A phase 3 study to evaluate the efficacy and safety of TAK-390MR [dexlansoprazole] (60 mg qd and 90 mg qd) compared to placebo on symptom relief in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD).

Trial Profile

A phase 3 study to evaluate the efficacy and safety of TAK-390MR [dexlansoprazole] (60 mg qd and 90 mg qd) compared to placebo on symptom relief in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD).

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2009 Actual patient number (908) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Takeda Global Research and Development Center added as trial affiliate and sponsor as reported by ClinicalTrials.gov.
    • 02 Jul 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top